IRB #

STUDY00020410

Title

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION

Principal Investigator

Adel Kardosh

Study Purpose

The purpose of the study is to compare the good and bad effects of atezolizumab plus bevacizumab, versus not receiving any treatment.

The study includes participants who have had surgery to remove their liver cancer and are at high risk of their cancer returning.

Medical Condition(s)

Hepatocellular Carcinoma

Eligibility Criteria

Inclusion
- 18 years or older
- Have had curative resection or ablation

Exclusion
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Evidence of residual, recurrent, or metastatic disease at randomization

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

1 year of study drug. After your final dose, your investigator will follow up with you about every 3 months for as long as you agree to it.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

F. Hoffmann-La Roche Ltd

Recruitment End

10/10/2025

Compensation Provided

No


Go Back